Flo Chardon (@FloChardon) header
Flo Chardon (@FloChardon) profile picture

Scientist and computational biology team lead at the Seattle Hub for Synthetic Biology at the Allen Institute. PhD with @JShendure and @lea_starita.

Seattle, WA
Joined February 2014
I also feel lucky that my interests outside of lab aligned so well with so many Shendure lab members! How special is it to have labmates that will go skiing with you before work? :) (also pictured is @sdomcke, another wonderful collaborator)
1
1
240
The cell type specificity we see, particularly at enhancers, is my favorite observation from this work. It was a treat to be able to do this screen in iPSC-derived neurons and see the striking contrast in enhancer upregulation btwn K562 cells and neurons!
1
1
138
Namely, we successfully validated our single-cell findings in singleton, bulk RNA-seq experiments and observed the expected upregulation in 11/13 cases.
1
2
267
Interestingly, EGFR Q791 and Y801 show differential resistance phenotypes between the covalent and noncovalent inhibitors, suggesting that these mutations do indeed affect drug binding. (11/n)
1
492
From this large-scale screen, we were super excited to see that 1) well-characterized resistance mutations were enriched in this screen, and 2) rare, and potentially novel resistance mutations were enriched in this screen when compared to synonymous variants. (9/n)
1
514
Our next experiment was a large scale, proof of concept screen in which we delivered 3,825 epegRNAs, programming 1,220 mutations across 7 genes, to PC-9 cells. We subjected these cells to 3 different EGFR inhibitors in various stages of clinical development. (8/n)
1
545
We knew that this framework would only be possible for large, pooled screens if the readout was the PE gRNA itself. To demonstrate that this was possible, we delivered a pool of 121 epegRNAs into PC-9 cells and saw resolution of resistant variants in multiple genes. (7/n)
1
575
The first experiment took months to work due to various technical challenges, but we were able to successfully install the EGFR C797S T>A mutation that renders lung adenocarcinoma cells resistant to osimertinib. This experiment was all I needed to move forward! (6/n)
1
716
Prime-SGE allows us to install and identify drug resistance mutations on a very large scale. (2/n)
1
2
1,284
A few weeks ago I defended my PhD thesis and I can't express how fulfilling the last 5 years have been in the @JShendure & @lea_starita labs. I feel like I hit the jackpot with my incredible advisors, labmates, & the @uwgenome department. Thanks to all who celebrated with me!
4
2
2
86
7,859
Plus, who doesn’t love looking at these beautiful neurons under the microscope! (24/n)
1
1
348
Maybe our favorite finding from this work is the extreme cell type specificity we see from targeting enhancer elements - these enhancer elements exclusively drive target gene upregulation of a single gene and only in a single cell type! (21/n)
1
5
421
Other examples include cases for which all successful gRNAs target a single TSS out of many candidate TSSs of a target gene (i.e. for TCF4, where all 5 gRNAs out of 14 gRNAs tested target the same TSS of TCF4). (18/n)
1
1
474
Such is the case for TBR1 - perhaps suggesting that the TBR1 promoter is in a largely closed, yet permissive state to activate transcription upon addition of the necessary trans acting factors, such as the activating domains that are brought in with CRISPRa. (17/n)
1
1
438
…We were able to first demonstrate that our differentiated neurons nicely overlay with mature neurons from her dataset when co-embedding the two datasets: (15/n)
1
2
468
We also saw instances (such as for ANK2) in which the most effective gRNAs targeted TSSs which would not be prioritized by biochemical (H3K27ac) and chromatin accessibility (ATAC) data alone. (11/n)
1
2
501
As an initial proof-of-concept - we demonstrated the ability of our screening framework to identify target gene upregulation in K562 cells from targeting both promoters and enhancers with CRISPRa perturbations. (10/n)
1
2
524